Drugs / 68Ga-PMD22
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT05937919 | May → Aug 2023 | digestive system cancer | Peking Union Medical College Hospital | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 68Ga-PMD22 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05937919 ↗ |
| Known as | PMD22 | “This study aimed to evaluate the safety and feasibility of a novel CLDN18.2-targeted nanobody, PMD22, labeled with gallium-68” PMID 38926162 ↗ Jun 2024 |
| Modality | Diagnostic / imaging agent | “a novel nanobody PET probe targeting CLDN18.2” PMID 38926162 ↗ Jun 2024 |
| Route | Intravenous | “68Ga-PMD22 were intravenous injected into the patients before PET/CT scans” NCT05937919 ↗ |
| Target | CLDN18 | “a novel nanobody PET probe targeting CLDN18.2” PMID 38926162 ↗ Jun 2024 |